SL
Therapeutic Areas
ArriVent Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Firmonertinib | 1L NSCLC with EGFR Exon 20 Insertion Mutations | Phase 3 |
| Firmonertinib + SHP2 inhibitor | 2L+ NSCLC with EGFR Classical Mutations | Phase 1 |
| ARR-217 | Gastrointestinal (GI) Tumors | Preclinical |
| ARR-002 | Solid Tumors | Discovery |
| ARR-421 | Solid Tumors | Discovery |
| ARR-173 | Solid Tumors | Discovery |
Leadership Team at ArriVent Biopharma
Z(
Zhengbin (Bing) Yao, PhD
Chief Executive Officer & Chairman
RL
Robin LaChapelle, MA
Chief Operating Officer
WK
Winston Kung, MBA
Chief Financial Officer
YW
Yang Wang, PhD
Chief Technology Officer
JK
James Kastenmayer, PhD, JD
General Counsel
BR
Brent Rice
Chief Commercial Officer